Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy

American Journal of Pathology

Volumn 177, Issue 2, 2010, Pages 1031-1041

  Johansson, Anna ^a,b   Rudolfsson, Stina ^a   Hammarsten, Peter ^a   Halin, Sofia ^a   Pietras, Kristian ^c   Jones, Jonathan ^d   Stattin, Pär ^a   Egevad, Lars ^c   Granfors, Torvald ^e   Wikström, Pernilla ^a   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e CENTRAL HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; COHORT ANALYSIS; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAST CELL; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE TUMOR; RAT; TUMOR GROWTH; UPREGULATION;

EID: 77957280758     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100070     Document Type: Article

References (52)

1. Cunha GR, Hayward SW, Wang YZ, Ricke WA: Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003, 107:1-10
2. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ: CCL2 as an important mediator of PC growth in vivo through the regulation of macrophage infiltration. Neoplasia 2007, 9:556-562
3. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A: Tumor associated macrophages in human PC: relation to clinicopathological variables and survival. Int J Oncol 2000, 17:445-451
4. Halin S, Häggström SR, Rooijen NV, Bergh A: Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia 2009, 11:177-186
5. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D: Inflammatory mast cells up regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999, 13:1382-1397
6. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI: Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007, 13:1211-1218
7. Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F, Lee DM, Zhang G, Glickman JN, Shin K, Rao VP, Poutahidis T, Weissleder R, McNagny KM, Khazaie K: Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA 2007, 104:19977-19982
8. Galinsky DS and Nechushtan H: Mast cells and cancer - no longer just basic science. Crit Rev Oncol Hematol 2008, 68:115-130
9. Wasiuk A, de Vries VC, Hartmann K, Roers A, Noelle RJ: Mast cells as regulators of adaptive immunity to tumors. Clin Exp Immunol 2009, 155:140-146
10. Kalesnikoff J, Galli SJ: New developments in mast cell biology. Nat Immunol 2008, 9:1215-1223
11. Galli SJ, Grimbaldeston M, Tsai M: Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008, 8:478-486
12. Nonomura N, Takayama H, Nishimura K, Oka D, Nakai Y, Shiba M, Tsujimura A, Nakayama M, Aozasa K, Okuyama A: Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of PC. Br J Cancer 2007, 97:952-956
13. Fleischmann A, Schlomm T, Köllermann J, Sekulic N, Huland H, Mirlacher M, Sauter G, Simon R, Erbersdobler A: Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 2009, 15:976-981
14. Pienta KJ, Bradley D: Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006, 12:1665-1671
15. Lissbrant IF, Häggström S, Damber JE, Bergh A: Testosterone stimulates angiogenesis and vascular re growth in the ventral prostate in castrated adult rats. Endocrinology 1998, 139:451-456
16. Smolev JK, Heston WD, Scott WW, Coffey DS: Characterization of the Dunning R3327 H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer. Cancer Treat Rep 1977, 61:273-287
17. Isaacs JT, Coffey DS: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981, 41:5070-5075
18. Halin S, Hammarsten P, Wikström P, Bergh A: Androgen-insensitive PC cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Prostate 2007, 67:370-377
19. Sullivan TJ, Parker CW: Pharmacologic modulation of inflammatory mediator release by rat mast cells. Am J Pathol 1976, 85:437-464
20. Johansson A, Jones J, Pietras K, Kilter S, Skytt A, Rudolfsson SH, Bergh A: A stroma targeted therapy enhances castration effects in a transplantable rat PC model. Prostate 2007, 67:1664-1676
21. Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, Egevad L, Mancini G, Lutz B, Bergh A, Fowler CJ: A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in PC. Eur J Cancer 2009, 45(1):174-82
22. Wikström P, Ohlson N, Stattin P, Bergh A: Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non-malignant human prostate tissue several months after castration therapy. Prostate 2007, 67:1277-1284
23. Johansson A, Häggström Rudolfsson S, Wikström P, Bergh A: Altered levels of Angiopoietin 1 and Tie 2 are associated with androgen-regulated vascular regression and growth in the ventral prostate in adult mice and rats. Endocrinology 2005, 146:3463-3470
24. Hungness SI, Akin C: Mastocytosis: advances in diagnosis and treatment. Curr Allergy Asthma Rep 2007, 7:248-254
25. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26:620-625
26. Pietras K, Pahler J, Bergers G, Hanahan D: Functions of paracrine PDGF signalling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008, 5:e19
27. Marshall JS, Jawdat DM: Mast cells in innate immunity. J Allergy Clin Immunol 2004, 114:21-27
28. Brzezińska-Błaszczyk E, Pietrzak A, Misiak-Tłoczek AH: Tumor necrosis factor (TNF) is a potent rat mast cell chemoattractant. J Interferon Cytokine Res 2007, 27:911-919
29. Rothschild AM: Mechanisms of histamine release by compound 48/80. Br J Pharmacol 1970, 38:253-262
30. Qian YX, McCloskey MA: Activation of mast cell K+ channels through multiple G proteinlinked Receptors Proc Natl Acad Sci USA 1993, 90:7844-7848
31. Gietzen K, Adamczyk-Engelmann P, Wüthrich A, Konstantinova A, Bader H: Compound 48/80 is a selective and powerful inhibitor of calmodulin-regulated functions. Biochim Biophys Acta 1983, 736:109-118
32. Bronner C, Wiggins C, Monté D, Märki F, Capron A, Landry Y, Franson RC: Compound 48/80 is a potent inhibitor of phospholipase C and a dual modulator of phospholipase A2 from human platelet. Biochim Biophys Acta 1987, 920:301-305
33. Starkey JR, Crowle PK, Taubenberger S: Mast cell deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988, 42:48-52
34. Kim SJ, Uehara H, Yazici S, Langley RR, He J, Tsan R, Fan D, Killion JJ, Fidler IJ: Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signalling and systemic administration of Paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 2004, 64: 4201-4208
35. Iamaroon A, Pongsiriwet S, Jittidecharaks S, Pattanaporn K, Prapayasatok S, Wanachantararak S: Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma. J Oral Pathol Med 2003, 32:195-199
36. Ribatti D, Crivellato E, Candussio L, Vacca A, Nico B, Benagiano V, Roncali L, Dammacco F: Angiogenic activity of rat mast cells in the chick embryo chorioallantoic membrane is down-regulated by treatment with recombinant human alpha-2a interferon and partly mediated by fibroblast growth factor-2. Haematologica 2002, 87:465-471
37. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP: Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001, 49:293-305
38. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S, Basilico C, Ittmann M: Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of PC. Cancer Res 2003, 63:5754-5760
39. Giri D, Ropiquet F, Ittmann M: Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human PC. Clin Cancer Res 1999, 5:1063-1071
40. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM: Inducible FGF-R1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007, 6:559-571
41. Casanovas O, Hicklin DJ, Bergers G, Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309
42. Coussens LM, Tinkle CL, Hanahan D, Werb Z: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490
43. Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, Gilks CB, Huntsman DG: Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat 2008, 107:249-257
44. Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M, Marzullo A, Herken R, Roncali L, Dammacco F: Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999, 79:451-455
45. Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P: Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 2003, 33:420-425
46. Yano H, Kinuta M, Tateishi H, Nakano Y, Matsui S, Monden T, Okamura J, Sakai M, Okamoto S: Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer 1999, 2:26-32
47. Allavena P, Sica A, Garlanda C, Mantovani A: The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008, 222:155-161
48. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM: Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009, 16:183-194
49. Johansson M, DeNardi DG, Coussens LM: Polarized immune responses differentially regulate cancer development. Immunol Rev 2008, 222:145-154
50. Cunha GR: Mesenchymal-epithelial interactions: past, present, future. Differentiation 2008, 76:578-586
51. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, Witte ON: Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 2007, 12:572-585
52. Ohlson N, Bergh A, Stattin P, Wikström P: Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels. Prostate 2007, 67:32-40